MEP30008A - Sustained release preparations - Google Patents

Sustained release preparations

Info

Publication number
MEP30008A
MEP30008A MEP-300/08A MEP30008A MEP30008A ME P30008 A MEP30008 A ME P30008A ME P30008 A MEP30008 A ME P30008A ME P30008 A MEP30008 A ME P30008A
Authority
ME
Montenegro
Prior art keywords
sustained release
release preparations
tacrolimus
hydrate
test
Prior art date
Application number
MEP-300/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Kazunari Yamashita
Eiji Hashimoto
Yukihiro Nomura
Fumio Shimojo
Shigeki Tamura
Takeo Hirose
Satoshi Ueda
Takashi Saitoh
Rinta Ibuki
Toshio Ideno
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26420115&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP30008(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MEP30008A publication Critical patent/MEP30008A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrane Compounds (AREA)
MEP-300/08A 1998-03-26 1999-03-25 Sustained release preparations MEP30008A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP7903998 1998-03-26
JP18296398 1998-06-29
YUP-580/00A RS50164B (sr) 1998-03-26 1999-03-25 Formulacije sa neprekidnim oslobađanjem
PCT/JP1999/001499 WO1999049863A1 (fr) 1998-03-26 1999-03-25 Preparations a liberation prolongee

Publications (1)

Publication Number Publication Date
MEP30008A true MEP30008A (en) 2010-10-10

Family

ID=26420115

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-300/08A MEP30008A (en) 1998-03-26 1999-03-25 Sustained release preparations
MEP-2008-300A ME00189B (me) 1998-03-26 1999-03-25 Preparati sa neprekidnim oslobađanjem

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2008-300A ME00189B (me) 1998-03-26 1999-03-25 Preparati sa neprekidnim oslobađanjem

Country Status (32)

Country Link
US (5) US6440458B1 (xx)
EP (3) EP2198858B1 (xx)
JP (4) JP3714970B2 (xx)
KR (3) KR100498765B1 (xx)
CN (1) CN1229111C (xx)
AR (1) AR023299A1 (xx)
AT (3) ATE514419T1 (xx)
AU (1) AU749623B2 (xx)
BR (1) BRPI9909201B8 (xx)
CA (1) CA2322516C (xx)
CZ (1) CZ300548B6 (xx)
DE (2) DE69918074T2 (xx)
DK (3) DK2198858T3 (xx)
ES (3) ES2219000T3 (xx)
HK (1) HK1038185A1 (xx)
HR (1) HRP20000707B1 (xx)
HU (1) HU230889B1 (xx)
ID (1) ID27825A (xx)
IL (1) IL138466A (xx)
ME (2) MEP30008A (xx)
NO (1) NO330578B1 (xx)
NZ (1) NZ507211A (xx)
PL (1) PL193244B1 (xx)
PT (3) PT1421939E (xx)
RS (1) RS50164B (xx)
RU (1) RU2214244C9 (xx)
SI (1) SI1064942T1 (xx)
SK (1) SK286887B6 (xx)
TR (1) TR200002771T2 (xx)
TW (2) TW570814B (xx)
WO (1) WO1999049863A1 (xx)
ZA (1) ZA200004963B (xx)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US7399480B2 (en) * 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
ES2219000T3 (es) * 1998-03-26 2004-11-16 Fujisawa Pharmaceutical Co., Ltd. Preparacion de liberacion sostenida de un compuesto macrolido.
US7455853B2 (en) * 1998-09-24 2008-11-25 Abbott Cardiovascular Systems Inc. Medical devices containing rapamycin analogs
US6855172B2 (en) 1998-10-13 2005-02-15 Dry, Inc. Dry-cleaning article, composition and methods
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
AU2001250365A1 (en) * 2000-03-08 2001-09-17 Awd Pharma Gmbh & Co. Kg Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients
EP2266549B1 (en) 2000-06-27 2019-08-07 Vectura Limited Method of making particles for use in a pharmaceutical composition
AU6926101A (en) * 2000-06-27 2002-01-08 Vectura Ltd Method of making particles for use in a pharmaceutical composition
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
CN1296043C (zh) 2001-02-19 2007-01-24 诺瓦提斯公司 式i的雷帕霉素化合物在制备用于治疗实体瘤的药物组合物中的用途
US6645946B1 (en) 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
JP4744782B2 (ja) 2001-03-27 2011-08-10 プロ−ファーマシューティカルズ，インク． 癌の治療のための化学療法剤との多糖の同時投与
GB0108498D0 (en) * 2001-04-04 2001-05-23 Novartis Ag Organic Compounds
JP2005512946A (ja) * 2001-05-09 2005-05-12 ノバルティス アクチエンゲゼルシャフト 選択的免疫調節法
AUPR529701A0 (en) * 2001-05-28 2001-06-21 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition
US20080145402A1 (en) * 2001-09-10 2008-06-19 Abbott Cardiovascular Systems Inc. Medical Devices Containing Rapamycin Analogs
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
WO2003037304A1 (en) * 2001-11-02 2003-05-08 Wockhardt Limited Controlled release compositions for macrolide antimicrobial agents
JP2003327536A (ja) * 2002-03-07 2003-11-19 Kitasato Inst:The ヒト免疫不全症候群ウイルスの感染、増殖抑制剤
BR0314013A (pt) * 2002-09-06 2005-07-12 Abbott Lab Equipamento médico contendo inibidor de hidratação
US7601695B2 (en) 2003-03-10 2009-10-13 Optimer Pharmaceuticals, Inc. Antibacterial agents
US20040185009A1 (en) * 2003-03-19 2004-09-23 Dexcel Pharma Technologies Ltd. Composition and device for treating periodontal diseases
GB0307867D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307866D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
AU2004249211A1 (en) * 2003-06-16 2004-12-29 Andrx Pharmaceuticals, Llc Oral extended-release composition
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
EP1641437A4 (en) * 2003-07-09 2009-06-03 Chong Kun Dang Pharm Corp SOLID DISPERSION OF TACROLIMUS
US20050043272A1 (en) * 2003-07-11 2005-02-24 Pro-Pharmaceuticals, Inc. Compositions and methods for hydrophobic drug delivery
PL1663216T3 (pl) 2003-08-29 2012-03-30 Veloxis Pharmaceuticals As Kompozycje o zmodyfikowanym uwalnianiu zawierające takrolimus
PT1663216E (pt) * 2003-08-29 2012-02-14 Veloxis Pharmaceuticals As Dispersões sólidas que compreendem tacrolímus
US20050053664A1 (en) * 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
WO2005032525A1 (en) * 2003-10-03 2005-04-14 Lifecycle Pharma A/S A method for preparing modified release pharmaceutical compositions
US7285544B2 (en) * 2003-11-18 2007-10-23 Bernstein Eric F Use of nitroxides in treating skin disease
KR100485877B1 (ko) * 2003-12-30 2005-04-28 종근당바이오 주식회사 타크롤리무스를 생산하는 미생물 및 이를 이용한타크롤리무스의 대량 생산방법
JP2007516951A (ja) * 2003-12-30 2007-06-28 アステラス製薬株式会社 気道閉塞症の治療または予防のためのマクロライドの使用
WO2005079314A2 (en) * 2004-02-13 2005-09-01 Pro-Pharmaceuticals, Inc. Compositions and methods used to treat acne and candida
WO2006017417A2 (en) * 2004-08-02 2006-02-16 Pro-Pharmaceuticals, Inc. Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins
WO2006021443A2 (en) * 2004-08-26 2006-03-02 Novartis Ag Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator
CN101076319A (zh) * 2004-09-29 2007-11-21 科迪斯公司 稳定的非晶形雷帕霉素样化合物的药物剂型
US7589100B2 (en) * 2004-12-01 2009-09-15 TEVA Gyógyszergyár Zártkörún Müködö Részvénytársaság Non-hygroscopic and powdery amorphous pimecrolimus
TW200635934A (en) * 2005-01-05 2006-10-16 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Amorphous tacrolimus and preparation thereof
KR100678824B1 (ko) * 2005-02-04 2007-02-05 한미약품 주식회사 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
KR20070121758A (ko) * 2005-03-17 2007-12-27 엘란 파마 인터내셔널 리미티드 나노입자형 면역 억제 화합물의 주사가능한 조성물
WO2007083316A2 (en) * 2006-01-23 2007-07-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Microspheres comprising nanocapsules containing a lipophilic drug
HUP0600097A3 (en) * 2006-02-08 2008-07-28 Richter Gedeon Nyrt Pharmaceutical compositions comprising tacrolimus and process for their preparation
JP2007308479A (ja) 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd 固体分散体製剤
EP2067475A4 (en) * 2006-09-26 2010-12-15 Astellas Pharma Inc PREPARATION FOR TACROLIMUS MAINTAINED RELEASE
EP1938804A1 (en) * 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
WO2008081829A1 (ja) * 2006-12-27 2008-07-10 Astellas Pharma Inc. 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ
MX2009006958A (es) * 2006-12-28 2009-07-09 Limerick Biopharma Inc Metodos y composiciones para tratamiento terapeutico.
US7521523B2 (en) 2006-12-28 2009-04-21 Eastman Chemical Company Oxygen-scavenging polyester compositions useful in packaging
JPWO2008084698A1 (ja) * 2006-12-28 2010-04-30 アステラス製薬株式会社 タクロリムス徐放性医薬組成物
US9044391B2 (en) 2007-01-10 2015-06-02 Board Of Regents, The University Of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
EA200970897A1 (ru) * 2007-03-29 2010-04-30 Панацея Биотек Лимитед Модифицированные лекарственные формы такролимуса
ITMI20070720A1 (it) * 2007-04-06 2008-10-07 Monteresearch Srl Composizioni orali contenenti tacrolimus in forma amorfa
WO2008135828A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8703204B2 (en) 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
WO2008145143A1 (en) 2007-05-30 2008-12-04 Lifecycle Pharma A/S Once daily oral dosage form comprising tacrolimus
US12083103B2 (en) 2007-05-30 2024-09-10 Veloxis Pharmaceuticals, Inc. Tacrolimus for improved treatment of transplant patients
WO2008149192A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
WO2009018338A2 (en) * 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Phosphorylated pyrone analogs and methods
HUE043897T2 (hu) * 2007-09-25 2019-09-30 Solubest Ltd Lipofil hatóanyagot tartalmazó készítmények és eljárás elõállításukra
WO2009055557A1 (en) 2007-10-25 2009-04-30 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
TW200932240A (en) 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
KR20090044269A (ko) * 2007-10-31 2009-05-07 (주)아모레퍼시픽 서방성 나노입자 및 이를 함유하는 화장료 조성물
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
WO2009073215A1 (en) 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
CL2008000374A1 (es) * 2008-02-05 2008-04-04 Igloo Zone Chile S A Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve
US8222272B2 (en) 2008-04-11 2012-07-17 Roxane Laboratories, Inc. Pharmaceutical formulation and process comprising a solid dispersion of macrolide (tacrolimus)
WO2010004304A1 (en) * 2008-06-17 2010-01-14 Biotica Technology Limited Novel compounds and methods for their production
EP3031460A1 (en) * 2008-10-24 2016-06-15 Cempra Pharmaceuticals Inc. Biodefenses using triazole-containing macrolides
EP2448406B1 (en) 2009-02-26 2016-04-20 Relmada Therapeutics, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
EP2475253B1 (en) 2009-09-10 2016-10-26 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and mac diseases
PL2575769T3 (pl) 2010-02-17 2016-12-30 Stabilizowana kompozycja takrolimusu
WO2011105070A1 (ja) 2010-02-25 2011-09-01 パナソニック株式会社 需給制御装置、需給制御方法、およびプログラム
US8697746B2 (en) 2010-07-14 2014-04-15 Senju Pharmaceutical Co., Ltd. Solid dispersion of alpha-ketoamide derivatives
MA34586B1 (fr) * 2010-08-25 2013-10-02 Medis Lab Particules cristallines de tacrolimus micronise a surface modifiee et compositions pharmaceutiques associees
KR20180110181A (ko) 2010-09-10 2018-10-08 셈프라 파마슈티컬스, 인크. 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드
CA2844827A1 (en) * 2011-08-16 2013-02-21 Merck Sharp & Dohme Corp. Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions
PE20141649A1 (es) * 2011-10-06 2014-11-14 Novartis Ag Composiciones farmaceuticas que comprenden 40-o-(2-hidroxi)etil-rapamicina
MX2014011537A (es) 2012-03-27 2015-02-10 Cempra Pharmaceuticals Inc Formulaciones parenterales para la administracion de antibioticos macrolidos.
EP2871188B1 (en) * 2012-07-06 2017-04-19 Godo Shusei Co., Ltd. Method for separating cyclic macrolide compound
RU2015138796A (ru) 2013-03-14 2017-04-19 Семпра Фармасьютикалс, Инк. Способы и составы для лечения респираторных заболеваний
EP2968384A4 (en) 2013-03-15 2017-02-15 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
US9168246B2 (en) 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
CN103432099A (zh) * 2013-08-13 2013-12-11 江苏正大清江制药有限公司 一种他克莫司缓释胶囊及其制备方法
WO2016078481A1 (zh) 2014-11-21 2016-05-26 杭州领业医药科技有限公司 一种含他克莫司的药物组合物及其制备方法
CN104473907A (zh) * 2014-12-25 2015-04-01 北京华禧联合科技发展有限公司 一种他克莫司的口服缓释制剂
US10576076B2 (en) 2015-05-20 2020-03-03 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
CN104840446B (zh) * 2015-05-27 2017-08-11 福建科瑞药业有限公司 一种他克莫司药物组合物及其制备方法
CA3021086C (en) 2016-04-15 2023-10-17 Bioatla, Llc Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
WO2018049174A1 (en) * 2016-09-08 2018-03-15 Synergistic Therapeutics, Llc Topical hair growth formulation
CN110114070A (zh) 2016-11-23 2019-08-09 诺华公司 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
KR102081176B1 (ko) * 2018-06-22 2020-02-25 주식회사 종근당 타크로리무스를 포함하는 서방형 약제학적 제제
WO2020131792A1 (en) * 2018-12-18 2020-06-25 Ddp Specialty Electronics Materials Us, Inc. A sustained release composition comprising an ethylcellulose
GR1009790B (el) 2019-03-20 2020-08-03 Φαρματεν Α.Β.Ε.Ε. Σκευασμα παρατεταμενης αποδεσμευσης που περιλαμβανει τακρολιμους

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL32929A (en) 1968-09-03 1973-08-29 Banker G Controlled-release pharmaceutical compositions containing a polymer for chemisorbing the active drug
US4127647A (en) * 1975-04-08 1978-11-28 Meiji Seika Kaisha, Ltd. Process for preparation of stable amorphous macrolide antibiotic solids
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
JPS62208103A (ja) 1986-03-07 1987-09-12 Yokogawa Hewlett Packard Ltd ロボツト運動制御システム
GB8608080D0 (en) 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
JPS63150220A (ja) * 1986-12-15 1988-06-22 Dainippon Pharmaceut Co Ltd 経口用固形製剤の製造方法
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
JP2822389B2 (ja) 1987-06-05 1998-11-11 藤沢薬品工業株式会社 抗ｆｒ−９００５０６物質抗体、および高感度酵素免疫測定法
JP2799208B2 (ja) 1987-12-09 1998-09-17 フアイソンズ・ピーエルシー マクロ環状化合物
DE3742525C2 (de) 1987-12-11 1998-02-19 Hertz Inst Heinrich Verfahren zur Herstellung von Metallalkylverbindungen und deren Verwendung
FR2624732B1 (fr) * 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
JPH02232814A (ja) 1989-03-07 1990-09-14 Fuji Photo Film Co Ltd 磁気記録媒体
ZA905202B (en) * 1989-07-05 1991-04-24 Fujisawa Pharmaceutical Co Aqueous liquid composition for external use
KR0159766B1 (ko) 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
ATE126803T1 (de) 1989-11-09 1995-09-15 Sandoz Ag Heteroatome enthaltende tricyclische verbindungen.
JPH03232814A (ja) * 1990-02-08 1991-10-16 Shin Etsu Chem Co Ltd 徐放性錠剤の製造方法
IE910847A1 (en) 1990-03-13 1991-09-25 Fisons Plc Immunosuppressive macrocyclic compounds
EP0533930A1 (en) 1990-06-11 1993-03-31 Fujisawa Pharmaceutical Co., Ltd. Use of a macrolide compound such as fk 506 for manufacturing a medicament for treating idiopathic thrombocytopenic purpura and basedow's disease
US5643901A (en) 1990-06-11 1997-07-01 Fujisawa Pharmaceutical Co., Ltd. Medicament for treating idiopathic thrombocytopenic purpura
MY110418A (en) 1990-07-02 1998-05-30 Novartis Ag Heteroatoms-containing tricyclic compounds.
EP0480623A1 (en) 1990-10-11 1992-04-15 Merck & Co. Inc. New halomacrolides and derivatives having immunosuppressive activity
US5208241A (en) 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
US5252732A (en) 1991-09-09 1993-10-12 Merck & Co., Inc. D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
US5247076A (en) 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
JP3128320B2 (ja) 1992-03-28 2001-01-29 株式会社常盤電機 不燃性シート及びその製造方法
GB9208492D0 (en) * 1992-04-16 1992-06-03 Glaxo Spa Heterocyclic compounds
GB9209882D0 (en) * 1992-05-07 1992-06-24 Glaxo Lab Sa Compositions
HUT66531A (en) 1992-05-07 1994-12-28 Sandoz Ag Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them
JP2707023B2 (ja) * 1992-07-01 1998-01-28 株式会社大塚製薬工場 経口吸収用製剤
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
AU686115B2 (en) 1992-11-02 1998-02-05 Fujisawa Pharmaceutical Co., Ltd. Imidazo (I,2-a) pyridine derivatives as bradykinin antagonists, pharmaceuticals and processes for their preparation
DE69326015T2 (de) * 1992-11-18 2000-02-03 Fujisawa Pharmaceutical Co., Ltd. Pharmazeutische zubereitung mit verlängerter wirkung
MY110603A (en) 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
US6204243B1 (en) * 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
DE4329503A1 (de) 1993-09-01 1995-03-02 Galenik Labor Freiburg Gmbh Pharmazeutische Präparate zur gezielten Behandlung von Morbus Crohn und Colitis Ulcerosa
JP3232814B2 (ja) 1993-09-22 2001-11-26 ジェイエスアール株式会社 感熱記録媒体用インキ組成物
HUT77530A (hu) * 1994-05-06 1998-05-28 Pfizer Inc. Azitromicint tartalmazó, szabályozott hatóanyag-felszabadítású dózisformák
AR004480A1 (es) 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
WO1997008182A1 (en) * 1995-08-24 1997-03-06 Merck & Co., Inc. Process for the preparation of imidazolyl macrolide immunosuppressants
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
TW426516B (en) 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
ES2219000T3 (es) * 1998-03-26 2004-11-16 Fujisawa Pharmaceutical Co., Ltd. Preparacion de liberacion sostenida de un compuesto macrolido.

Also Published As

Publication number Publication date
TW200306867A (en) 2003-12-01
CZ300548B6 (cs) 2009-06-10
US6884433B2 (en) 2005-04-26
AU749623B2 (en) 2002-06-27
ES2367294T3 (es) 2011-11-02
CA2322516C (en) 2010-10-05
EP1064942B9 (en) 2011-03-02
EP1064942A1 (en) 2001-01-03
KR20030040556A (ko) 2003-05-22
KR100440553B1 (ko) 2004-07-15
PT1421939E (pt) 2010-07-12
PT1064942E (pt) 2004-10-29
DE69918074T2 (de) 2004-11-04
US8551522B2 (en) 2013-10-08
CN1229111C (zh) 2005-11-30
EP2198858A1 (en) 2010-06-23
DE69942286D1 (de) 2010-06-02
ES2343248T9 (es) 2011-08-23
PL193244B1 (pl) 2007-01-31
EP1064942B1 (en) 2004-06-16
AR023299A1 (es) 2002-09-04
EP1064942A4 (en) 2002-09-04
HUP0101237A3 (en) 2002-06-28
PL343096A1 (en) 2001-07-30
KR20040007751A (ko) 2004-01-24
DK2198858T3 (da) 2011-10-03
HK1038185A1 (en) 2002-03-08
JP2004354394A (ja) 2004-12-16
US20090074858A1 (en) 2009-03-19
HUP0101237A1 (hu) 2001-09-28
TWI235068B (en) 2005-07-01
JP4992845B2 (ja) 2012-08-08
JP4622382B2 (ja) 2011-02-02
WO1999049863A1 (fr) 1999-10-07
TR200002771T2 (tr) 2001-02-21
US20050169993A1 (en) 2005-08-04
ES2219000T3 (es) 2004-11-16
RS50164B (sr) 2009-05-06
YU58000A (sh) 2003-08-29
ES2343248T3 (es) 2010-07-27
JP2004352727A (ja) 2004-12-16
TW570814B (en) 2004-01-11
NO330578B1 (no) 2011-05-16
ATE514419T1 (de) 2011-07-15
US6576259B2 (en) 2003-06-10
RU2214244C9 (ru) 2020-07-29
KR20010042083A (ko) 2001-05-25
JP3992031B2 (ja) 2007-10-17
KR100505464B1 (ko) 2005-08-04
RU2214244C2 (ru) 2003-10-20
JP2009007369A (ja) 2009-01-15
ATE269075T1 (de) 2004-07-15
HRP20000707B1 (en) 2005-06-30
SK14392000A3 (sk) 2001-03-12
IL138466A (en) 2005-11-20
ID27825A (id) 2001-04-26
PT2198858E (pt) 2011-09-01
BRPI9909201B8 (pt) 2021-05-25
EP1421939A1 (en) 2004-05-26
JP3714970B2 (ja) 2005-11-09
NO20004773D0 (no) 2000-09-25
EP1421939B9 (en) 2011-03-02
SI1064942T1 (en) 2004-12-31
CN1301157A (zh) 2001-06-27
DK1421939T5 (da) 2011-07-18
NO20004773L (no) 2000-11-23
IL138466A0 (en) 2001-10-31
EP2198858B1 (en) 2011-06-29
EP1421939B1 (en) 2010-04-21
ME00189B (me) 2011-02-10
KR100498765B1 (ko) 2005-07-01
US20030235614A1 (en) 2003-12-25
US20020044967A1 (en) 2002-04-18
AU2856399A (en) 1999-10-18
SK286887B6 (sk) 2009-07-06
NZ507211A (en) 2003-07-25
DK1421939T3 (da) 2010-08-09
HU230889B1 (hu) 2018-12-28
US6440458B1 (en) 2002-08-27
HRP20000707A2 (en) 2001-12-31
BR9909201A (pt) 2000-11-14
CZ20003549A3 (cs) 2001-04-11
RU2000126836A (ru) 2002-09-10
ATE464900T1 (de) 2010-05-15
CA2322516A1 (en) 1999-10-07
DK1064942T3 (da) 2004-11-01
BRPI9909201B1 (pt) 2019-04-02
ZA200004963B (en) 2002-03-27
DE69918074D1 (de) 2004-07-22

Similar Documents

Publication Publication Date Title
MEP30008A (en) Sustained release preparations
YU35893A (sh) Formulacije oksidona sa kontrolisanim otpuštanjem i njihova upotreba
EA200000246A1 (ru) Быстро дезинтегрирующие таблетки метилцеллюлозы
NO980669D0 (no) Orale raskt-opplöselige blandinger for dopaminagonister
RU2004108111A (ru) Пленка, освежающая дыхание
CY1107384T1 (el) Ταχεως διασπειρομενες μορφες δοσομετρησεως ανευ ζελατινης
EA200000245A1 (ru) Быстро дезинтегрирующие таблетки метилцеллюлозы
HRP20020198B1 (en) Moxifloxacin formulation containing common salt
ATE391495T1 (de) Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe
ATE450250T1 (de) Stabile zusammensetzung enhaltend partikel in einer gefrorenen wässrigen matrix
DE69622510D1 (de) Nifedipinzubereitung mit langanhaltender Freisetzung
RS52577B (en) ONE-DAY OXYCODON FORMULATIONS
ATE340574T1 (de) Neue dosisformen von substituierten benzimidazolen und verfahren zur deren verwendung
HRP20010243B1 (en) Compositions containing diphosphonic acids
RS50360B (sr) Farmaceutske formulacije derivata platine
DK0801559T3 (da) Fremgangsmåde til fremstilling af orale doseringsformer indeholdende et beta-lactam antibiotikum
HRP20050544A2 (en) Solid drug for oral use
NO20092662L (no) Sammensetning med forlenget frigjoring og fremgangsmate for a produsere det samme
HUP0204202A2 (hu) Ibuprofent tartalmazó hatóanyag-preparátum, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények
ATE203392T1 (de) Stabilisierte pseudoemulsionen und verfahren zu ihrer herstellung
DK1104289T3 (da) Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister
MEP31308A (en) Lyophilized and liquid preparations comprising a polysaccharide derivative of camptothecin
HRP20020181B1 (hr) Farmaceutski pripravci koji sadrže derivat benzamida kao aktivan sastojak
ME00568B (me) Vodena farmaceutska kompozicija koja sadrži ciklesonid
HRP20010764B1 (en) Prucalopride oral solution